Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 10 SUPPL. 2, 1999, Pages

  Fox, Wallace ^a   Ellard, Gordon A ^b   Mitchison, Denis A ^b  

^a St George's Hospital Medical School ^*  (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; THIOACETAZONE;

CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG FORMULATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER TOXICITY; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLICATION; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED KINGDOM;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; CONTROLLED CLINICAL TRIALS; GREAT BRITAIN; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 0032821532     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (573)

1. Hart P D. Chemotherapy of tuberculosis - research during the past 100 years. Br Med J 1946; 2: 805, 849.
2. East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972: 1079-1085.
3. Hill L E, Nunn A J, Fox W. Matching quality of agents employed in 'double-blind' controlled clinical trials. Lancet 1976; 1: 352-356.
4. Darbyshire J, Fox W, Girling D J, Nunn A J, Mitchison D A. Short-course chemotherapy for tuberculosis. Am Rev Respir Dis 1981; 124: 658-660.
5. Das S, Chan S L, Allen B W, Mitchison D A, Lowrie D B. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Hong before, during and after short-course chemotherapy. Tubercle Lung Dis 1993; 74: 47-51.
6. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
7. Singapore Tuberculosis Service/British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988; 137: 1147-1150.
8. Radhakrishna S, Sutherland I. The chance occurrence of substantial initial differences between groups in studies based on random allocation. App Stat 1962; 9: 47-54.
9. Tall R, Devine C M. The use of a computer in the organization of a large-scale co-operative controlled clinical trial of the treatment of pulmonary tuberculosis. Bull WHO 1970; 43: 127-141.
10. Devine C M, Tall R, Nunn AJ, Mitchison DA. Computer-aided procedures in a multi-centre co-operative controlled clinical trial in pulmonary tuberculosis. Tubercle 1971; 52: 199-218.
11. Fox W. Recent developments in controlled trials in pulmonary tuberculosis. Br Med Bull 1954; 10: 108-114.
12. Fox W. The scope of the controlled clinical trial illustrated by studies of pulmonary tuberculosis. Bull WHO 1971; 45: 559-572.
13. Medical Research Council. Streptomycin treatment of tuberculous meningitis. Lancet 1948; 1: 582-596.
14. Medical Research Council. Streptomycin in acute miliary tuberculosis. Lancet 1950; 1: 841-846.
15. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769-782.
16. Medical Research Council. Specific laboratory tests in streptomycin therapy of tuberculosis. Lancet 1948; 2: 862-865.
17. Ministry of Health. Streptomycin in the treatment of tuberculosis. Lancet 1949; 1: 273-276.
18. Sutherland I. Medical Research Council Streptomycin Trial. In: Armitage P, Colton T, eds. Encyclopaedia of Biostatistics. Chichester, England: John Wiley and Sons, 1998; 3: 2554-2562
19. Fox W, Sutherland I, Daniels M. A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis. Q J Med 1954; 23: 347-366.
20. Mitchison D A. Tests for streptomycin sensitivity of tubercle bacilli in Tween 80 albumin liquid medium. Lancet 1949; 2: 694-698.
21. Crofton J, Mitchison D A. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948; 2: 1009-1015.
22. Mitchison D A. The segregation of streptomycin-resistant variants of Mycobacterium tuberculosis into groups with characteristic levels of resistance. J Gen Microbiol 1951; 5: 596-604.
23. Mitchison D A. The occurrence of independent mutations to different types of streptomycin resistance in Bacterium coli. J Gen Microbiol 1953; 8: 168-185.
24. Mitchison D A. Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis. Results of simultaneous sensitivity tests in liquid and on solid media. Thorax 1950; 5: 144-161.
25. Medical Research Council. Prophylactic streptomycin in thoracoplasty operations. Thorax 1951; 6: 17-24.
26. Medical Research Council. Streptomycin treatment of tuberculous lesions of the trachea and bronchi. Lancet 1951; 1: 253-257.
27. Bignall J R, Crofton J W, Thomas J A B. Effect of streptomycin on vestibular function. Br Med J 1951; 1: 554-559.
28. Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. Br Med J 1950; 2: 1073-1085.
29. Fox W, Sutherland I. A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis. Q J Med 1956; 25: 221-243.
30. Medical Research Council. The prevention of streptomycin resistance by combined chemotherapy. Br Med J 1952; 1: 1157-1162.
31. Daniels M, Bradford Hill A. Chemotherapy of pulmonary tuberculosis in young adults. Br Med J 1952; 1: 1162-1168.
32. Fox W, Sutherland I. A five-year assessment of patients in a controlled trial of streptomycin with different doses of paraaminosalicylic acid in pulmonary tuberculosis. Q J Med 1959; 28: 77-95.
33. Mitchison D A. The behaviour of mixtures of streptomycin-sensitive and -resistant tubercle bacilli in liquid medium sensitivity tests. Thorax 1950; 5: 162-168.
34. Bignall J R, Clegg J W, Crofton J W, Douglas Smith B J, Holt H D, Mitchison D A. Intermittent dosage in the treatment of pulmonary tuberculosis with streptomycin. Br Med J 1950; 1: 1224-1230.
35. Daniels M. Clinical evaluation of chemotherapy in tuberculosis. Brit Med Bull 1951; 7 No.4: 320-326.
36. Medical Research Council. The treatment of pulmonary tuberculosis with isoniazid. Br Med J 1952; 2: 735-746.
37. Fox W. The Medical Research Council trials of isoniazid. Recent results of combined chemotherapy. Bull Int Union Tuberc 1953; 23: 292-307.
38. Medical Research Council. Isoniazid in the treatment of pulmonary tuberculosis. Second Report. Br Med J 1953; 1: 521-536.
39. Medical Research Council. Emergence of bacterial resistance in pulmonary tuberculosis under treatment with isoniazid, streptomycin plus PAS, and streptomycin plus isoniazid. Lancet 1953; 2: 217-223.
40. Medical Research Council. Isoniazid in combination with streptomycin or with PAS in the treatment of pulmonary tuberculosis. Br Med J 1953; 2: 1005-1014.
41. Medical Research Council. Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis. Br Med J 1955; 1: 435-445.
42. Medical Research Council. Changes in isoniazid resistance of tubercle bacilli after cessation of treatment. Thorax 1954; 9: 254-259.
43. Mitchison D A. Titration of strains of tubercle bacillli against isoniazid. Lancet 1952; 2: 858-860.
44. Mitchison D A. Comparison of techniques for measuring the isoniazid resistance of tubercle bacilli. J Clin Pathol 1953; 6: 118-123.
45. Medical Research Council, Tuberculosis Chemotherapy Trials Committee, Laboratory Sub-Committee. Laboratory techniques for the determination of sensitivity of tubercle bacilli to isoniazid, streptomycin, and PAS. Lancet 1953; 2: 213-217.
46. Mitchison D A, Monk M. Comparison of solid and liquid medium sensitivity tests of tubercle bacilli to para-aminosalicylic acid. J Clin Pathol 1955; 8: 229-236.
47. Barnett M, Bushby S R M, Mitchison D A. Isoniazid-resistant strains of tubercle bacilli. Their development and stability. Lancet 1953; 1: 314-320.
48. Mitchison D A. Culture media for tubercle bacilli during chemotherapy with isoniazid. Tubercle 1954; 35: 170-172.
49. Barnett M, Bushby S R M, Mitchison D A. Tubercle bacilli resistant to isoniazid: Virulence and response to treatment with isoniazid in guinea-pigs and mice. Br J Exp Pathol 1953; 34: 568-581.
50. Mitchison D A. Virulence of isoniazid-resistant tubercle bacilli. Am Rev Tuberc 1954; 69: 640-641.
51. Mitchison D A. Tubercle bacilli resistant to isoniazid. Virulence and response to treatment with isoniazid in guinea-pigs. Br Med J 1954; 1: 128-130.
52. Mitchison D A. The ecology of tubercle bacilli resistant to streptomycin and isoniazid. In: Gale E F and Davies R, eds. Adaptation in micro-organisms. Cambridge, UK: Cambridge University Press, 1953: pp 253-274.
53. Mitchison D A. Problems of drug resistance. Br Med Bull 1954; 10: 115-124.
54. Fox W, Sutherland I. The clinical significance of positive cultures and of isoniazid-resistant bacilli during the treatment of pulmonary tuberculosis. Thorax 1955; 10: 85-98.
55. Fox W, Wiener A, Mitchison D A, Selkon J B, Sutherland I. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: A national survey, 1955-56. Tubercle 1957; 38: 71-84.
56. Mitchison D A, Selkon J B. Bacteriological aspects of a survey of the incidence of drug-resistant tubercle bacilli among untreated patients. Tubercle 1957; 38: 85-98.
57. Medical Research Council. Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation. Tubercle 1962; 43: 201-267.
58. Kent P W, Fox W, Miller A B, Nunn A J, Tall R, Mitchison D A. The therapy of pulmonary tuberculosis in Kenya: a comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment services. Tubercle 1970; 51: 24-38.
59. Medical Research Council. Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. Tubercle 1973; 54: 99-129.
60. Hutton P W, Lutalo Y K, Williams A W, Tonkin I M, Fox W. Acute pulmonary tuberculosis in East Africans: a controlled trial of isoniazid in combination with streptomycin or PAS. Tubercle 1956; 37: 151-165.
61. Fox W, Hutton P W, Sutherland I, Williams A W. A comparison of acute extensive pulmonary tuberculosis and its response to chemotherapy in Britain and Uganda. Tubercle 1956; 37: 435-450.
62. Williams A W, Pepys J. East African/British Medical Research Council Tuberculosis Investigations. West Afr Med J 1959; 8: 289.
63. East African Hospitals/Medical Research Council. Comparative trial of isoniazid alone in low and high dosage and isoniazid plus PAS in the treatment of acute pulmonary tuberculosis in East Africans. Tubercle 1960; 41: 83-102.
64. East African Hospitals/British Medical Research Council. Comparative trial of isoniazid in combination with sulphone or PAS in the treatment of acute pulmonary tuberculosis in East Africans. Tubercle 1959; 40: 1-13.
65. East African Hospitals/British Medical Research Council. Comparative trial of isoniazid in combination with thiacetazone or a substituted diphenylthiourea (SU1906) or PAS in the treatment of acute pulmonary tuberculosis in East Africans. Tubercle 1960; 41: 399-423.
66. East African/British Medical Research Councils. Isoniazid with thiacetazone in the treatment of pulmonary tuberculosis in East Africa - second investigation. Tubercle 1963; 44: 301-333.
67. East African/British Medical Research Council. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa - third investigation. Tubercle 1966; 47: 1-32.
68. Tuberculosis Chemotherapy Centre, Madras. Isoniazid plus thiacetazone compared with two regimens of isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis in South Indian patients. Bull World Health Organ 1966; 34: 483-515.
69. East African/British Medical Research Council. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa - fourth investigation: The effect of increasing the dosage of isoniazid. Tubercle 1966; 47: 315-339.
70. East African/British Medical Research Council. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa - fifth investigation. Tubercle 1970; 51: 123-151.
71. East African/British Medical Research Council. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa - second report of fifth investigation. Tubercle 1970; 51: 353-358.
72. East African/British Medical Research Council. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa - third report of fifth investigation. Tubercle 1973; 54: 169-179.
73. Briggs I L, Rochester W R, Shennan D H, Riddell R W, Fox W, Heffernan J E, Miller A B, Nunn A J, Stott H, Tall R. Streptomycin plus thiacetazone (thioacetazone) compared with streptomycin plus PAS and with isoniazid plus thiacetazone in the treatment of pulmonary tuberculosis in Rhodesia. Tubercle 1968; 49: 48-69.
74. Hong Kong Anti-tuberculosis Association and Government Tuberculosis Service/British Medical Research Council. A controlled comparison of thiacetazone (thioacetazone) plus isoniazid with PAS plus isoniazid in Hong Kong. Tubercle 1968; 49: 243-280.
75. Singapore Tuberculosis Services/Brompton Hospital/British Medical Research Council. A controlled clinical trial of the role of thiacetazone-containing regimens in the treatment of pulmonary tuberculosis in Singapore. Tubercle 1971; 52: 88-116.
76. Singapore Tuberculosis Services/Brompton Hospital/British Medical Research Council. A controlled clinical trial of the role of thiacetazone-containing regimens in the treatment of pulmonary tuberculosis in Singapore: Second Report. Tubercle 1974; 55: 251-260.
77. Selkon J B, Devadatra S, Kulkarni K G, Mitchison D A, Nair C N, Ramachandran K. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull World Health Organ 1964; 31: 273-294.
78. Mitchison D A. Plasma concentrations of isoniazid in the treatment of tuberculosis. In: Davies D S, Prichard B N C, eds. Biological effects of drugs in relation to their plasma concentrations. Macmillan, London: British Pharmacological Society 1973: pp 171-182.
79. East African/British Medical Research Council Investigation (1969). The results from twelve to thirty-six months in patients submitted to two studies of primary chemotherapy for pulmonary tuberculosis in East Africa. Tubercle, Lond. 1969; 50: 233-256.
80. Miller A B, Fox W, Tall R. An international co-operative investigation into thiacetazone (thioacetazone) side-effects. Tubercle 1966; 47: 33-74.
81. Miller A B, Nunn A J, Robinson D K, Ferguson G C, Fox W, Tall R. A second international co-operative investigation into thiacetazone side-effects 1. The influence of a vitamin and antihistamine supplement. Bull World Health Organ 1970; 43: 107-125.
82. Miller A B, Nunn A J, Robinson D K, Fox W, Somasunderam P R, Tall R. A second international cooperative investigation into thioacetazone side-effects 2. Frequency and geographical distribution of side-effects. Bull World Health Organ 1972; 47: 211-227.
83. Ferguson G C, Nunn A J, Fox W, Miller A B, Robinson D K, Tall R. A second international co-operative investigation into thiacetazone side-effects. Rashes on two thiacetazone containing regimens. Tubercle 1971; 52: 166-181.
84. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1959; 21: 51-144.
85. Dawson J J Y, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan C V, Somasundaram P R, Stott H, Tripathy S P, Velu S. A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. Bull World Health Organ 1966; 34: 533-551.
86. Andrews R H, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan C V, Velu S. Prevalence of tuberculosis among close family contacts of tuberculous patients in South India, and influence of segregation of the patient on the early attack rate. Bull World Health Organ 1960; 23: 463-510.
87. Ramakrisnan C V, Andrews R H, Devadatta S, Fox W, Radhakrishna S, Somasundaram P R, Velu S. Influence of segregation of tuberculosis patients for one year on the attack rate of tuberculosis in a 2-year period in close family contacts in South India. Bull World Health Organ 1961; 24: 129-148.
88. Kamat S R, Dawson J J Y, Devadatta S, Fox W, Janardhanam B, Radhakrishna S, Ramakrishnan C V, Somasundaram P R, Stott H, Velu S. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ 1966; 34: 517-532.
89. Ramakrishnan C V, Andrews R H, Devadatta S, Fox W, Radhakrishna S, Somasundaram P R, Velu S. Prevalence and early attack rate of tuberculosis among close family contacts of tuberculous patients in South India under domiciliary treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 1961; 25: 361-407.
90. Devadatta S, Dawson J J Y, Fox W, Janardhanam B, Radhakrishna S, Ramakrishnan C V, Velu S. Attack rate of tuberculosis in a 5-year period among close family contacts of tuberculous patients under domiciliary treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 1970; 42: 337-351.
91. Fox W. The chemotherapy and epidemiology of tuberculosis. Some findings of general applicability from the Tuberculosis Chemotherapy Centre, Madras. Lancet 1962; 2: 413-417, 473-478.
92. Fox W. Ambulatory chemotherapy in a developing country: Clinical and epidemiological studies. Adv Tuherc Res 1963; 12: 28-149.
93. Fox W. Realistic chemotherapeutic policies for tuberculosis in the developing countries. Br Med J 1964; 1: 135-142.
94. Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 1958; 39: 269-274.
95. Fox W. Self-administration of medicaments. A review of published work and a study of the problem. Conference Proceedings, Toronto, 1961. Amsterdam: Excerpta Medica, International Congress Series, 1962, no. 44, I: pp 307-331.
96. Fox W. The role of ambulatory chemotherapy in technically advanced developing countries and the problems of its supervision. 3rd International Congress of Chemotherapy. Stuttgart: Georg Thieme Verlag, 1964.
97. Mitchison D A, Selkon J B, Weiner A. A case of pulmonary tuberculosis due to isoniazid-resistant, guinea-pig attenuated, Mycobacterium tuberculosis. Tubercle 1957; 38: 382-386.
98. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1960; 23: 535-585.
99. Selkon J B, Fox W, Gangadharam P R J, Ramachandaram K, Ramakrishnan C V, Velu S. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS. Bull World Health Organ 1961; 25: 779-792.
100. Tuberculosis Chemotherapy Centre, Madras. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 1. An assessment of two vitamin B preparations and glutamic acid. Bull World Health Organ 1963; 28: 455-475.
101. Tuberculosis Chemotherapy Centre, Madras. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 2. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull World Health Organ 1963; 29: 457-481.
102. Gangharam P R J, Bhatia A L, Radhakrishna S, Selkon J B. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis 1. Microbiological assay of isoniazid in serum following a standard intramuscular dose. Bull World Health Organ 1961; 25: 765-777.
103. Gangadharam P R J, Devadatta S, Fox W, Nair C N, Selkon J B. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS. Bull World Health Organ 1961; 25: 793-806.
104. Devadatta S, Gangadharam P R J, Andrews R H, Fox W, Ramakrishnan C V, Selkon J B, Velu S. Peripheral neuritis due to isoniazid. Bull World Health Organ 1960; 23: 587-598.
105. Ramakrishnan C V, Rajendran K, Jacob P G, Fox W, Radhakrishna S. The role of diet in the treatment of pulmonary tuberculosis. Bull World Health Organ 1961; 25: 339-359.
106. Ramakrishnan C V, Rajendran K, Mohan K, Fox W, Radhakrishna S. The diet, physical activity and accommodation of patients with quiescent pulmonary tuberculosis in a poor South Indian community. Bull World Health Organ 1966; 34: 553-571.
107. Krishnamurthy D V, Selkon J B, Ramachandran K, Devadatta S, Mitchison D A, Radhakrishna S, Stott H. Effect of pyridoxine on vitamin B6 concentrations and glutamic-oxaloacetic transaminase activity in whole blood of tuberculous patients receiving high-dosage isoniazid. Bull World Health Organ 1967; 36: 853-870.
108. Devadatta S, Bhatia A L, Andrews R H, Fox W, Mitchison D A, Radhakrishna S, Ramakrishnan C V, Selkon J B, Velu S. Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 1961; 25: 807-829.
109. East African/British Medical Research Council. Influence of pretreatment bacterial resistance to isoniazid, thiacetazone or PAS on the response to chemotherapy of African patients with pulmonary tuberculosis. Tubercle 1963; 44: 393-416.
110. Tripathy S P, Menon N K, Mitchison D A, Narayana A S L, Somasundaram P A, Stott H, Velu S. Response to treatment with isoniazid plus PAS of tuberculous patients with primary isoniazid resistance. Tubercle 1969; 50: 257-268.
111. Ramakrishnan C V, Bhatia A L, Devadatta S, Fox W, Narayana A S L, Selkon J B, Velu S. The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance to isoniazid: response to continued treatment for a second year with isoniazid alone or with isoniazid plus PAS. Bull World Health Organ 1962; 26: 1-18.
112. Velu S, Andrews R H, Angel J H, Devadatta S, Fox W, Gangadharam P R J, Narayana A S L, Ramkrishnan C V, Selkon J B, Somasundaram P R. Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate. Bull World Health Organ 1961; 25: 409-429.
113. Vein S, Andrews R H, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan C V, Selkon J B, Somasundaram P R, Subbaiah T V. Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate. Bull World Health Organ 1960; 23: 511-533.
114. Devadatta S, Andrews R H, Angel J H, Bharia A L, Fox W, Janardhanam B, Radhakrishna S, Ramakrishnan C V, Subbaiah T V, Velu S. Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate. Bull World Health Organ 1961; 24: 149-175.
115. Evans C, Devadatta S, Fox W, Gangadharam P R J, Menon N K, Ramakrishnan C V, Sivasubramanian S, Somasundaram P R, Stott H, Velu S. A 5-year study of patients with pulmonary tuberculosis treated at home in a controlled comparison of isoniazid plus PAS with 3 regimens of isoniazid alone. Bull World Health Organ 1969; 41: 1-16.
116. Nazareth O, Devadatta S, Fox W, Menon N K, Radhakrishna S, Rajappa D, Ramakrishnan C V, Somasundaram P R, Stott H, Subbammal S, Velu S. Two controlled studies of the efficacy of isoniazid alone in preventing relapse in patients with bacteriologically quiescent pulmonary tuberculosis at the end of one year of chemotherapy. Bull World Health Organ 1971; 45: 603-615.
117. Tuberculosis Chemotherapy Centre, Madras. Intermittent treatment of pulmonary tuberculosis. A concurrent comparison of twice-weekly isoniazid plus streptomycin and daily isoniazid plus p-aminosalicylic acid in domiciliary treatment. Lancet 1963; 1: 1078-1080.
118. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of intermittent (twice-weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis. Bull World Health Organ 1964; 31: 247-271.
119. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull World Health Organ 1970; 43: 143-206.
120. Nazareth O, Devadatta S, Evans C, Fox W, Janardhanam B, Menon N K, Radhakrishna S, Ramakrishnan C V, Stott H, Tripathy S P, Velu S. A two-year follow-up of patients with quiescent pulmonary tuberculosis following a year of chemotherapy with an intermittent (twice-weekly) regimen of isoniazid plus streptomycin or a daily regimen of isoniazid plus PAS. Tubercle 1966; 47: 178-189.
121. Ramakrishnan C V, Devadatta S, Evans C, Fox W, Meno N K, Nazareth O, Radhakrishna S, Sambamoorthy S, Stott H, Tripathy S P, Velu S. A four-year follow-up of patients with quiescent pulmonary tuberculosis at the end of a year of chemotherapy with twice-weekly isoniazid plus streptomycin or daily isoniazid plus PAS. Tubercle 1969; 50: 115-124.
122. Ramakrishnan C V, Janardhanam B, Krishnamurthy D V, Stott H, Subbammal S, Tripathy S P. Toxicity of pyrazinamide, administered once weekly in high dosage, in tuberculous patients. Bull World Health Organ 1968; 39: 775-779.
123. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of two fully supervised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis. Tubercle 1973; 54: 23-45.
124. Ellard G A, Gammon P T, Lakshminarayan S, Fox W, Aber V R, Mitchison D A, Citron K M, Tall R. Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosis. Lancet 1972; 1: 340-343.
125. Ellard G A, Gammon P T, Polansky F, Viznerova A, Havlik I, Fox W. Further studies on the pharmacology of a slow-release matrix preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis. Tubercle 1973; 54: 57-66.
126. Sarma G R, Kailasam S, Mitchison D A, Nair N G K, Radhakrishna S, Tripathy S P. Studies of serial plasma isoniazid concentrations with different doses of a slow-release preparation of isoniazid. Tubercle 1975; 56: 314-323.
127. Parthasarathy R, Davadatta S, Fox W, Krishnaswami K V, Radhakrishna S, Somasundaram P R, Tripathy S P. Studies of immediate adverse reactions to different doses of a slow-release preparation of isoniazid. Tubercle 1976; 57: 115-121.
128. Santha T, Fox W, Nazareth O, Prabhakar R, Radhakrishna S, Ramakrishnan C V, Sivasubramanian S, Somasundaram P R, Tripathy S P. Study of adverse reactions to a once-weekly regimen of streptomycin plus a slow-release preparation of isoniazid in high dosage for six months. Tubercle 1976; 57: 123-130.
129. Ellard G A. A slow-release preparation of isoniazid: Pharmacological aspects. Bull Int Union Tuberc 1977; 51: 143-154.
130. Ellard G A, Gammon P T, Tiitinen H. Determination of the acetylator phenotype using matrix isoniazid. Tubercle 1975; 56: 203-209.
131. Ellard G A, Gammon P T. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmacol 1977; 4: 5-14.
132. WHO Collaborating Centre for Tuberculosis Chemotherapy, Prague. A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. Bull World Health Organ 1971; 45: 573-592.
133. WHO Collaborating Centre for Tuberculosis Chemotherapy, Prague. A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. 2. The results from 12 to 24 months. Bull World Health Organ 1973; 48: 155-165.
134. WHO Collaborating Centre for Tuberculosis Chemotherapy, Prague. A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. III. Third report: the results to 36 months. Tubercle 1976; 57: 45-48.
135. Tuberculosis Chemotherapy Centre, Madras. Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis. Br Med J 1973; 2: 7-11.
136. East African/British Medical Research Council. A pilot study of two regimens of intermittent thiacetazone plus isoniazid in the treatment of pulmonary tuberculosis in East Africa. Tubercle 1974; 55: 211-221.
137. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Lancet 1975; 2: 1105-1109.
138. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months. Am Rev Respir Dis 1977; 116: 807-820.
139. WHO Collaborating Centre for Tuberculosis Chemotherapy, Prague. A study of two twice-weekly and a once-weekly continuation regimen of tuberculosis chemotherapy, including a comparison of two durations of treatment 1. First report: The results at 18 months. Tubercle 1976; 57: 235-249.
140. WHO Collaborating Centre for Tuberculosis Chemotherapy, Prague. A study of two twice-weekly and a once-weekly continuation regimen of tuberculosis chemotherapy, including a comparison of two durations of treatment 2. Second report: The results at 36 months. Tubercle 1977; 58: 129-136.
141. Tuberculosis Research Centre, Madras. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis - a controlled trial of four regimens. Tubercle 1981; 61: 13-29.
142. Fox W, Stark A J, Tall R, Bhatia J L, Clarke J H C, Donia T O, Krishnaswami K V, Oussedik N. A study of adverse reactions to high intermittent thiacetazone. Tubercle 1974; 55: 29-40.
143. Dickinson J M, Ellard G A, Mitchison D A. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle 1968; 49: 351-366.
144. Velu S, Andrews R H, Devadatta S, Fox W, Ramakrishnan C V, Subbaiah T V. The results of treatment with streptomycin plus pyrazinamide in patients with active pulmonary tuberculosis despite prolonged treatment with isoniazid plus PAS. Indian J Tuberc 1960; 7: 85-94.
145. Velu S, Andrews R H, Angel J H, Devadatta S, Fox W, Jacob P G, Nair C N, Ramakrishnan C V. Streptomycin plus pyrazinamide in the treatment of patients excreting isoniazid-resistant tubercle bacilli, following previous chemotherapy. Tubercle 1961; 42: 136-147.
146. Velu S, Dawson J J Y, Devadatta S, Fox W, Kulkarni K G, Mohan K, Ramakrishnan C V, Stott H. A controlled comparison of streptomycin plus pyrazinamide and streptomycin plus PAS in the retreatment of patients excreting isoniazid-resistant organisms. Tubercle 1964; 45: 14-159.
147. Velu S, Sambamoorthy S. A note on the relapse rate over a four-year period in patients with quiescent pulmonary tuberculosis following treatment with reserve regimens. Tubercle 1968; 49: 410-412.
148. Angel J H, Bhatia A L, Devadatta S, Fox W, Janardhanam B, Radhakrishna S, Ramakrishnan C V, Selkon J B, Stott H, Velu S. A controlled comparison of cycloserine plus ethionamide with cycloserine plus thiacetazone in patients with active pulmonary tuberculosis despite prolonged previous chemotherapy. Tubercle 1963; 44: 215-224.
149. Rao N V N, Eidus L, Evans C, Kailasam S, Radhakrishna S, Somasundaram P R, Stott H, Subbammal S, Tripathy S P. Deterioration of cycloserine in the tropics. Bull World Health Organ 1968; 39: 781-789.
150. Ramakrishnan C V, Devadatta S, Evans C, Kamat S R, Menon N K, Radhakrishna S, Rajagopalan S, Stott H, Tripathy S P, Velu S. Cycloserine plus ethionamide in the treatment of patients excreting isoniazid-resistant tubercle bacilli following previous chemotherapy. Tubercle 1967; 48: 114-127.
151. East African/British Medical Research Council. A comparison of two regimens of streptomycin plus PAS in the retreatment of pulmonary tuberculosis. Tubercle 1968; 49: 70-78.
152. East African/British Medical Research Council. Streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis - second report. Tubercle 1970; 51: 359-374.
153. East African/British Medical Research Council. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969; 50: 81-114.
154. Fox W, Robinson D K, Tall R, Mitchison D A, Kent P W, Macfadyen D M. A study of acute intolerance to ethionamide, including a comparison with prothionamide, and of the influence of a vitamin B-complex additive in prophylaxis. Tubercle 1969; 50: 125-143.
155. Devadatta S, Menon N K, Nazareth O, Radhakrishna S, Ramakrishnan C V, Somasundaram P R, Usha S P, Velu S. A double-blind study to determine the maximum tolerated dose of ethionamide, when administered twice-weekly to patients with pulmonary tuberculosis. Tubercle 1970; 51: 263-269.
156. East African/British Medical Research +ouncil. Streptomycin plus PAS plus pyrazinamide in the retreatment of pulmonary tuberculosis in East Africa. Tubercle 1971; 52: 191-198.
157. East African/British Medical Research Council. Streptomycin plus PAS plus pyrazinamide in the retreatment of pulmonary tuberculosis in East Africa: Second report. Tubercle 1973; 54: 283-290.
158. Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council. A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong. Tubercle 1974; 55: 1-27.
159. Horsfall P A L, Girling D J. Daily and intermittent regimens of ethambutol plus rifampicin in the treatment of failure patients (a one-year report). 22nd International Tuberculosis Conference, Tokyo. Excerpta Medica 1973: pp 71-78.
160. Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council. A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: Results up to 30 months. Tubercle 1975; 56: 179-189.
161. Babu Swai O, Aluoch J A, Githui W A, Thiong'o R, Edwards E A, Darbyshire J H, Nunn A J. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. Tubercle 1988; 69: 5-14.
162. Allen B W, Mitchison D A, Chan Y C, Yew W W, Allan W G L, Girling D J. Amikacin in the treatment of pulmonary tuberculosis. Tubercle 1983; 64: 111-118.
163. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis 1992; 73: 59-67.
164. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy in Hong Kong. Second report: The results at 12 months. Tubercle 1974; 55: 193-210.
165. Hong Kong Tuberculosis Treatment Services/Singapore Tuberculosis Service/Royal Postgraduate Medical School/British Medical Research Council. Lack of association between rifampicin-dependent antibodies and bacteriological response during intermittent rifampicin treatment. J Antimicrob Chemother 1976; 2: 265-270.
166. East African/British Medical Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1973; 1: 1331-1339.
167. East African/British Medical Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet 1974; 2: 237-240.
168. East African/British Medical Research Council. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1977; 116: 3-8.
169. East African/British Medical Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for the treatment of pulmonary tuberculosis. Lancet 1974; 2: 1100-1106.
170. East African/British Medical Research Council. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Am Rev Respir Dis 1976; 114: 471-475.
171. East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. First report. Am Rev Respir Dis 1978; 118: 39-48.
172. East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Third Study. Second Report. Tubercle 1980; 61: 59-69.
173. East African/British Medical Research Council. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report. Lancet 1978; 2: 334-338.
174. East African/British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis: Second report of the 4th study. Am Rev Respir Dis 1981; 123: 165-170.
175. East And Central African/British Medical Research Council. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tubercle 1983; 64: 153-166.
176. East And Central African/British Medical Research Council (fifth Collaborative Study). Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: Final report. Tubercle 1986; 67: 5-15.
177. Tanzania/British Medical Research Council Study. Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985; 131: 727-731.
178. A Kenyan/Zambian/British Medical Research Council Collaborative Study. Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1989; 140: 990-995.
179. Tanzania/British Medical Research Council. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. S Afr Med J 1996; 86: 960-965.
180. Jindani A, Aber V R, Edwards E A, Mitchison D A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-949.
181. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Tubercle 1975; 56: 81-96.
182. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis 1977; 115: 727-735.
183. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1978; 118: 219-227.
184. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months. Tubercle 1979; 60: 201-210.
185. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981; i: 171-174.
186. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: The results up to 24 months. Tubercle 1982; 63: 89-98.
187. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month, 3 × weekly regimens for smear-positive pulmonary tuberculosis, incuding an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Am Rev Respir Dis 1991; 143: 700-706.
188. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 1991; 143: 262-267.
189. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 579-585.
190. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: The results up to 30 months. Tubercle 1981; 62: 95-102.
191. Singapore Tuberculosis Service/British Medical Research Council. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 779-783.
192. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985; 132: 374-378.
193. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991; 143: 707-712.
194. Hong Kong Chest Service/British Medical Research Council. Study of a fully supervised programme of chemotherapy for pulmonary tuberculosis given once weekly in the continuation phase in the rural areas of Hong Kong. Tubercle 1984; 65: 5-15.
195. Ellard G A, Ellard D R, Allen B W, Girling D J, Nunn A J, Teo S K, Tan T H, Ng H K, Chan S L. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986; 133: 1076-1080.
196. Fox W. Drug combinations and the bioavailability of rifampicm. Tubercle 1990; 71: 241-245.
197. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance and adverse reactions when isoniazid, rifampin and pyrazinamide are given as a combined formulation or separately during three-times-weekly anti-tuberculosis chemotherapy. Am Rev Respir Dis 1989; 140: 1618-1622.
198. Tuberculosis Research Centre. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 1983; 64: 73-91.
199. Santha T, Nazareth O, Krishnamurthy S, Balasubramanian R, Vijayan V K, Janardhanam B, Venkataraman P, Tripathy S P, Prabhakar R. Treatment of pulmonary tuberculosis with short-course chemotherapy in South India - 5 year follow up. Tubercle 1989; 70: 229-234.
200. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Am Rev Respir Dis 1986; 134: 27-33.
201. Balasubramanian R. Fully intermittent six month regimens for pulmonary tuberculosis in South India. Indian J Tuberc 91; 38: 51-53.
202. Algerian Working Group/British Medical Research Council. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am Rev Respir Dis 1984; 129: 921-928.
203. Berkani M, Chaulet P, Darbyshire J H, Nunn A, Fox W. Results of a therapeutic trial comparing a six month and a twelve month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Rev Mal Respir 1986; 3: 73-85.
204. Algerian Working Group/British Medical Research Council. Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Tubercle 1991; 72: 88-100.
205. Hong Kong Tuberculosis Treatment Services and East African/British Medical Research Councils. First-line chemotherapy in the retreatment of bacteriological relapses of pulmonary tuberculosis following a short-course regimen. Lancet 1976; 1: 162-163.
206. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
207. Medical Research Council. Chemotherapy of pulmonary tuberculosis with pneumoconiosis. First report. Tubercle 1963; 44: 47-70.
208. Medical Research Council. Chemotherapy of pulmonary tuberculosis with pneumoconiosis. Second report. Tubercle 1967; 48: 1-10.
209. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
210. Mitchison D A. Prophylactic chemotherapy. Adv Tuberc Res 1957: 8: 304-316.
211. Hong Kong Chest Service/Tuberculosis Research Centre Madras/British Medical Research Council. A study of the characteristics and course of sputum smear-negative pulmonary tuberculosis. Tubercle 1981; 62: 155-167.
212. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Sputum-smear-negative pulmonary tuberculosis. Controlled trial of 3-month and 2-month regimens of chemotherapy. First Report. Lancet 1979; 1: 1361-1364.
213. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: The results at 30 months. Am Rev Respir Dis 1981; 124: 138-142.
214. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: Results at 60 months. Am Rev Respir Dis 1984; 130: 23-28.
215. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Am Rev Respir Dis 1989; 139: 871-876.
216. Medical Research Council Working Party of Tuberculosis of the Spine. A controlled trial of ambulant out-patient treatment and in-patient rest in bed in the management of tuberculosis of the spine in young Korean patients on standard chemotherapy. J Bone Joint Surg [Br] 1973; 55B: 678-697.
217. Medical Research Council Working Party on Tuberculosis of the Spine. 5th Report. A five-year assessment of controlled trials of in-patient and out-patient treatment and of plaster-of-paris jackets for tuberculosis of the spine in children on standard chemotherapy. J Bone Joint Surg [Br] 1976; 58B: 399-411.
218. Medical Research Council Working Party on Tuberculosis of the Spine. 9th Report. A 10-year assessment of controlled trials of in-patient and out-patient treatment and of plaster-of-paris jackets for tuberculosis of the spine in children on standard chemotherapy. J Bone Joint Surg [Br] 1985; 67-B: 103-110.
219. Medical Research Council Working Party on Tuberculosis of the Spine. 2nd Report. A controlled trial of plaster-of-paris jackets in the management of ambulatory outpatient treatment of tuberculosis of the spine in children on standard chemotherapy: A study in Pusan, Korea. Tubercle 1973; 54: 261-282.
220. Medical Research Council Working Party on Tuberculosis of the Spine. 3rd Report. A controlled trial of debridement and ambulatory treatment in the management of tuberculosis of the spine in patients on standard chemotherapy. A study in Bulawayo, Rhodesia. J Trop Med Hyg 1974; April: 71-92.
221. Medical Research Council Working Party on Tuberculosis of the Spine. 6th Report. Five-year assessments of controlled trials of ambulatory treatment, debridement and anterior spinal fusion in the management of tuberculosis of the spine. Studies in Bulawayo (Rhodesia) and in Hong Kong. J Bone Joint Surg [Br] 1978; 60-B: 163-177.
222. Medical Research Council Working Party on Tuberculosis of the Spine. 4th Report. A controlled trial of anterior spinal fusion and debridement in the surgical management of tuberculosis of the spine in patients on standard chemotherapy: A study in Hong Kong. Br J Surg 1974; 61: 853-866.
223. Medical Research Council Working Party on Tuberculosis of the Spine. 8th Report. A 10-year assessment of a controlled trial comparing debridement and anterior spinal fusion in the management of tuberculosis of the spine in patients on standard chemotherapy in Hong Kong. J Bone Joint Surg [Br] 1982; 64-B: 393-398.
224. Medical Research Council Working Party on Tuberculosis of the Spine. 7th Report. A controlled trial of anterior spinal fusion and debridement in the surgical management of tuberculosis of the spine in patients on standard chemotherapy: A study in two centres in South Africa. Tubercle 1978; 59: 79-105.
225. Medical Research Council Working Party on Tuberculosis of the Spine. 10th Report. A controlled trial of six-month and nine-month regimens of chemotherapy in patients undergoing radical surgery for tuberculosis of the spine in Hong Kong. Tubercle 1967; 67: 243-259.
226. Indian Council of Medical Research/British Medical Research Council South India. A controlled trial of short-course regimens of chemotherapy in patients receiving ambulatory treatment or undergoing radical surgery for tuberculosis of the spine. Indian J Tuberc 1989; 36 (Suppl): 1-21.
227. Medical Research Council Working Party on Tuberculosis of the Spine. 12th Report. Controlled trial of short-course regimens of chemotherapy in the ambulatory treatment of spinal tuberculosis. J Bone Joint Surg [Br] 1993; 75: 240-248.
228. Strang J I G, Gibson D G, Nunn A J, Kakaza H H S, Girling D J, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987; 2: 1418-1422.
229. Strang J I G, Gibson D G, Mitchison D A, Girling D J, Fox W, Kakaza H H S, Allen B W, Evans D J, Nunn A J. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 1988; 759-764.
230. Girling D J, Darbyshire J H, Humphries M J, O'Mahoney G. Extra-pulmonary tuberculosis. Br Med Bull 1988; 44: 738-756.
231. Ellard G A, Mitchison D A, Girling D J, Nunn A J, Fox W. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. Am Rev Respir Dis 1978; 118: 143-144.
232. Mitchison D A, Allen B W, Gabriel M, Nunn A J. Sensitive microbiological method for the detection of rifampicin in urine. Tubercle 1974; 55: 245-248.
233. Aquinas M, Allan W G L, Horsfall P A L, Jenkins P K, Wong H Y, Girling D, Tall R, Fox W. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J 1972; 1: 765-771.
234. Girling D J. Clinical observations on adverse reactions. Scand J Respir Dis 1973; 84 (Suppl): 119-124.
235. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. A controlled clinical trail of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy. Clin Allergy 1974; 4: 1-12.
236. Girling D J. Immunological reactions to intermittent rifampicin. Symposium on rifampicin in tuberculosis treatment, Helsinki, Feb 22-23, 1974: pp 125-138
237. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. Investigation of allergic status and blood counts in chinese patients receiving daily or intermittent rifampicin in Hong Kong. Clin Allergy 1975; 5: 189-199.
238. Hong Kong Tuberculosis Treatment Services/Britih Medical Research Council. The influence of age and sex on the incidence of the 'flu' syndrome and rifampicin-dependent antibodies in patients on intermittent rifampicin for tuberculosis. Tubercle 1975; 56: 173-178.
239. Dickinson J M, Mitchison D A, Lee S K, Ong Y Y, O'Mahoney M G, Girling D J, Nunn A J. Serum rifampicin concentration related to dose size and to the incidence of the 'flu' syndrome during intermittent rifampicin administration. J Antimicrob Chemother 1977; 3: 445-452.
240. Worlledge S. Hong Kong Tuberculosis Treatment Services/ Royal Postgraduate Medical School/British Medical Research Council co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. The detection of rifampicin-dependent antibodies. Proceedings of the Workshop on Intermittent Drug Therapy and Immunological Implications in Antituberculous Treatment with Rifampicin. Scand J Respir Dis 1973; 84 (Suppl): 60.
241. Worlledge S. Hong Kong Tuberculosis Treatment Services/ Royal Postgraduate Medical School/British Medical Research Council co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Correlation between the presence of rifampicin-dependent antibodies and the clinical data. Proceedings of the Workshop on Intermittent Drug Therapy and Immunological Implications in Antituberculous Treatment with Rifampicin. Scand J Respir Dis 1973; 84 (Suppl): 125.
242. Girling D J. Adverse reactions to rifampicin in antituberculosis regimens. J Antimicrob Chemother 1977; 3: 115-132.
243. Girling D J, Hitze K L. Adverse reactions to rifampicin. Bull World Health Organ 1979; 57: 45-49.
244. Ellard G A, Haslam R M. Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide. Tubercle 1976; 57: 97-103.
245. Horsfall P A L, Plummer J, Allan W G L, Girling D J, Nunn A J, Fox W. Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration. Tubercle 1979; 60: 13-24.
246. Jenner P J, Ellard G A, Allan W G L, Singh D, Girling D J, Nunn A J. Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore. Tubercle 1981; 62: 175-179.
247. Girling D J. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978; 59: 13-32.
248. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong. Tubercle 1976; 57: 81-95.
249. Girling D J. Adverse effects of antituberculosis drugs. Drugs 1982; 23: 56-74.
250. Medical Research Council Working Party on Tuberculosis of the Spine. 14th report. Five year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Int Orthop 1999; 23: 73-81.
251. Stott H, Peto J, Stephens R, Fox W, Sutherland I, Foster-Carter A F, Teare H D, Penning J. An assessment of the carcinogenicity of isoniazid in patients with pulmonary tuberculosis. Tubercle 1976; 57: 1-15.
252. Pattison P R M, Kun O J, Friedmann A I, Darbyshire J H, Tall R. Ethambutol and intra-ocular pressure. Tubercle 1978; 59: 33-40.
253. Humber D P, Nsanzumuhire H, Aluoch J A, Webster A D B, Aber V R, Mitchison D A, Girling D J, Nunn A J. Controlled double-blind study of the effect of rifampin on humoral and cellular immune responses in patients with pulmonary tuberculosis and in tuberculosis contacts. Am Rev Respir Dis 1980; 122: 425-436.
254. Chan S L, Yew W W, Ma W K, Girling D J, Aber V R, Felmingham D, Allen B W, Mitchison D A. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tubercle Lung Dis 1992; 73: 33-38.
255. Sirgel F A, Botha F J H, Parkin D P, Van de Wal B W, Donald P R, Clark P K, Mitchison D A. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts. A new method of drug assessment. J Antimicrob Chemother 1993; 32: 867-875.
256. Botha F J H, Sirgel F A, Parkin D P, Van de Wal B W, Donald P R, Mitchison D A. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (rifater) in patients with pulmonary tuberculosis. S Afr Med J 1996; 86: 155-158.
257. Donald P R, Sirgel F A, Botha F J, Seifart H I, Parkin D P, Vandenplas M L, Van de Wal B W, Maritz J S, Mitchison D A. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 895-900.
258. Sirgel F A, Botha F J, Parkin D P, Van de Wal B W, Schall R, Donald P R, Mitchison D A. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 901-905.
259. Mitchison D A, Ellard G A. Antituberculous drugs. In: Reeves D S, Phillips I, Williams J D, Wise R, eds. Laboratory methods in antimicrobial chemotherapy. Edinburgh: Churchill Livingstone, 1978: pp 244-248.
260. Mitchison D A, Sturm W A. The measurement of early bactericidal activity. In: Malin A, McAdam K P W J, eds. Bailliere's Clinical Infectious Diseases: Mycobacterial Diseases Part II, Tindall, London: Bailliere 1997; 2: 185-206.
261. Dickinson J M, Mitchison D A. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987; 68: 113-118.
262. Mitchison D A, Ellard G A, Grosset J. New antibacterial drugs for the treatment of mycobacterial disease in man. Br Med Bull 1988; 44: 757-774.
263. Dhillon J, Dickinson J M, Guy J A, Ng T K, Mitchison D A. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tubercle Lung Dis 1992; 73: 116-123.
264. Chan S L, Yew W W, Porter J H D, McAdam K P W J, Allen B W, Dickinson J M, Ellard G A, Mitchison D A. Comparison of Chinese and Western rifapentines and improvement in bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994; 3: 267-274.
265. Tam C M, Chan S L, Lam C W, Leung C C, Kam K M, Morris J S, Mitchison D A. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: Initial report. Am J Respir Crit Care Med 1998; 157: 1726-1733.
266. Tam C M, Chan S L, Lam C W, Dickinson J M, Mitchison D A. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997; 1: 411-416.
267. Mitchison D A. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 1998; 2(8): 612-615.
268. Mitchison D A. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. J Appl Bacteriol 1996; 81: S72-80.
269. Mitchison D A. How drug resistance emerges as a result of poor compliance during short-course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
270. Johnston R N, Mitchison D A, Selkon J B, Stradling P. Chemotherapy for the 'good chronic'. Tubercle 1957; 38: 309-315.
271. Lefford M J. The treatment of tuberculosis. Br Med Abstracts 1970: 76-88.
272. Mitchison D A. Reserve Drug Combinations. J Irish Med Assoc 1970: 63: 86-91.
273. Mitchison D A. New antituberculosis regimens. In: Turner P, ed. Advanced Medicine, Topics in Therapeutics 2. Tunbridge Wells: Pitman Medical, 1976: pp 12-25.
274. Fox W. The John Barnwell lecture. Changing concepts in the chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1968; 97: 767-790.
275. Fox W. Current standard chemotherapy of tuberculosis. In: Tala E, ed. Postgraduate Meeting on Modern Treatment of Tuberculosis. Finland: University Central Hospital of Turku, 1972: pp 1-20.
276. Fox W. Advances in the treatment of respiratory tuberculosis. Practitioner 1970; 205: 502-513.
277. Fox W. General considerations in intermittent drug therapy of pulmonary tuberculosis. Postgrad Med J 1971; 47: 729-736.
278. Fox W. General considerations in the choice and management of regimens of chemotherapy for pulmonary tuberculosis. Bull Int Union Tuberc Lung Dis 1972; 47: 49-67.
279. Girling D J. Some recent advances in the chemotherapy of pulmonary tuberculosis. Ann Acad Med, Singapore 1973: 2.
280. Fox W. Consideraciones generales sobre la quimioterapia intermitente de la tuberculosis pulmonari. Bull Pan Am Health Organ 1974; Vol 77, No. 2.
281. Girling D J. The chemotherapy of tuberculosis. In: Ratledge C, Stanford J, Grange J M, eds. The biology of mycobacteria - clinical aspects of mycobacterial disease. London, San Diego: Academic Press 1989; 3: 285-323.
282. Ellard G A. The treatment of tuberculosis and leprosy. Lepr Rev 1975; 45: 149-155.
283. Fox W. Chemotherapy in developing countries: Proceedings of the 18th International Conference on Tuberculosis. Bull Int Union Tuberc 1966; 37: 249-260.
284. Fox W. Problems of treatment of drug resistance in the developing countries. Tubercle 1969; 50(S): 55-65.
285. Fox W, Mitchison D A. State of the Art. Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1975; 111: 325-353.
286. Girling D J, Heffernan J F, Fox W, Mitchison D A. Short-course chemotherapy of tuberculosis. Lancet 1976; 1: 358.
287. Fox W. The modern management and therapy of pulmonary tuberculosis. Philip Ellman Lecture. Proc R Soc Med 1977; 70: 4-15.
288. Girling D J. Recent advances in the treatment of pulmonary tuberculosis. Advanced Medicine 13. Tunhridge Wells: Pitman Medical, 1977: pp 263-277.
289. Mitchison D A, Grosset J, Aquinas S M, Tripathy S P, Darbyshire J, Friedlin A G. Chemotherapy of tuberculosis. Cur Chemother Immunother 1978: 43-47.
290. Fox W. The current status and prospects of short-course chemotherapy. Holland: Selected Papers, 1978; 18: 32-56.
291. Fox W. Short-course chemotherapy for tuberculosis: regimens and prospects. The First President Manuel Luis Quezon Memorial Lecture. Chest Dis 1978; June: 3-16.
292. Fox W. The current status of short-course chemotherapy. Bull Int Union Tuberc 1978; 53(4): 268-280.
293. Fox W. The chemotherapy of pulmonary tuberculosis: A review. Chest 1979; 76S: 785S-796S.
294. Stott H. The treatment of pulmonary tuberculosis in the developing countries. Trans R Soc Trop Med Hyg 1978; 72: 564-569.
295. Girling D J, Fox W, Mitchison D A. Chemotherapy for pulmonary tuberculosis. Lancet 1980; 2: 979-980.
296. Fox W. Short-course chemotherapy for tuberculosis. Recent Advances in Respiratory Medicine 1980; 2: 183-203.
297. Girling D J. Principles of antimicrobial treatment - tuberculosis. In: Scientific Foundations of Respiratory Medicine. London: Heinemann, 1981: pp 617-630.
298. Girling D J. Treatment of tuberculosis. Postgrad Doc-Asia 1981; July/Aug: 161-171.
299. Fox W. Whither short-course chemotherapy?. Br J Dis Chest 1981; 75: 331-357.
300. Girling D J. The treatment of tuberculosis in childhood: current concepts and practice. In: Paediatrics in the Tropics. Oxford: Oxford Medical Publications, 1981: pp 262-277.
301. Citron K M, Girling D J. Tuberculosis. In: Oxford Textbook of Medicine. Oxford: Oxford University Press, 1983: pp 5237-5260.
302. Fox W. Short-course chemotherapy for pulmonary tuberculosis. In: Advanced Medicine 19. Tunbridge Wells: Pitman Medical 1983: pp 307-326.
303. Fox W. Prerusovana Chemoterapie Plicni Tuberkulozy se zvlastnim zretelem k prinosu Strediska SZO spolupracujicim na chemoterapii tuberkulozy v Praze. Casopis Lekaru Ceskych 1984; 123: 153-157.
304. Aber V R, Nunn A J. Factors affecting relapse following short-course chemotherapy. Bull Int Union Tuberc 1978; 53: 260-264.
305. Mitchison D A. Bacteriology of tuberculosis. Trop Doct 1974; 4: 147-153.
306. Allen B W. Tuberculosis bacteriology in developing countries. Med Lab Sci 1984; 41: 400-409.
307. Allen B W. A dual purpose gas burner for use in microbiological safety cabinets. Med Lab Sci 1977; 34: 277-278.
308. Mitchison D A. Examination of sputum by smear and culture in case-finding. Bull Int Union Tuberc 1968; 41: 139-147.
309. Allen B W, Darrell J H. Contamination of specimen container surfaces during sputum collection. J Clin Pathol 1983; 36: 479-481.
310. Allen B W, Darrell J H. Extrapulmonary tuberculosis: A potential source of laboratory-acquired infection. J Clin Pathol 1981; 34: 404-407.
311. Clancey J K, Allen B W, Rogers D T, Smith L S, Aber V, Mitchison D A. Comparison of machine and manual staining of direct smears for acid-fast bacilli by fluorescence microscopy. J Clin Pathol 1976; 29: 931-933.
312. Holst E, Mitchison D A, Radhakrishna S. Examination of smears for tubercle bacilli by fluorescence microscopy. Indian J Med Res 1959; 47: 495-499.
313. Mitchison D A. Bacteriological aspects of mycobacterial infections. Br Med J 1972; 1: 424-425.
314. Mitchison D A. Standard smears for grading the content of acid-fast bacilli in sputum. Tubercle 1966; 47: 289-291.
315. Allen B W, Mitchison D A. Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med Lab Sci 1992; 49: 94-98.
316. Thomas K L, Ramamurthi V, Ramamurthi V V. A method of cleaning microscope slides for their repeated use in the examination of sputum for tubercle bacilli. Tubercle 1962: 43; 299-300.
317. Allen B W. Survival of tubercle bacilli in heat-fixed sputum smears. J Clin Pathol 1981; 34: 719-722.
318. Allen B W. Excretion of viable tubercle bacilli by Blatta orientalis (the oriental cockroach) following ingestion of heat-fixed sputum smears: A laboratory investigation. Trans R Soc Trop Med Hyg 1987; 81: 98-99.
319. Allen B W, Hinkes W F. Koch's stain for tubercle bacilli. Postgrad Doc 1982; Middle East 5: 108-111, Africa 4: 115-117 , Asia 2: 84-86.
320. Allen B W, Hinkes W F. Koch's stain for tubercle bacilli. Postgrad Doc 1982; Middle East 5: 108-111, Africa 4: 115-117 , Asia 2: 84-86.
321. Allen B W, Hinkes W F. Koch's stain for tubercle bacilli. Postgrad Doc 1982; Middle East 5: 108-111, Africa 4: 115-117 , Asia 2: 84-86.
322. Allen B W, Hinkes W F. Koch's stain for tubercle bacilli. Postgrad Doc 1982; Middle East 5: 108-111, Africa 4: 115-117 , Asia 2: 84-86.
323. Allen B W, Hinkes W F. Koch's cultivation of tubercle bacilli. Med Lab Sci 1983; 40: 85-87.
324. Mitchison R S, Allen B W, Mitchison D A. False positive acid fast smears. Lancet 1975; 2: 281.
325. Subhaiah T V, Selkon J B, Bhatia A L, Mitchison D A, Radhakrishna S. The addition of para-aminobenzoic acid or catalase to Lowenstein-Jensen medium and the effect of prolonged incubation in the culture of tubercle bacilli. Tubercle 1960; 41: 334-340.
326. Subbaiah T V, Selkon J B, Bhatia A L, Radhakrishna S, Mitchison D A. Addition of catalase to Lowenst Ein-Jensen medium. Tubercle 1961; 42: 537-538.
327. Mitchison D A, Allen B W, Carrol L, Dickinson J M, Aber V R. A selective oleic acid albumin agar medium tor tubercle bacilli. J Med Microbiol 1971; 5: 165-175.
328. Mitchison D A, Allen B W, Lambert R A. Selective media in the isolation of tubercle bacilli from tissues. J Clin Pathol 1973; 26: 250-252.
329. Mitchison D A, Aber V R. Culture of specimens other than sputum for mycobacteria. J Clin Pathol 1974; 27: 883-887.
330. Allen B W, Mitchison D A, Darbyshire J, Chew W W K, Gabriel M. Examination of operation specimens from patients with spinal tuberculosis for tubercle bacilli. J Clin Pathol 1983; 36: 662-666.
331. Mitchison D A, Allen B W, Manickavasagar D. Selective Kirchner medium in the culture of specimens other than sputum for mycobacteria. J Clin Pathol 1983; 36: 1357-1361.
332. Allen B W. Inhibitory effect of rubber on the growth of M. tuberculosis. Tubercle 1980; 61: 91-95.
333. Allen B W, Swaffield J E. Mycobacterium tuberculosis: Recovery from contaminated culture media and identification of bacteria responsible for contamination. Med Lab Sci 1982; 39: 11-13.
334. Allen B W. In-vitro inhibition of mycobacteria by viridans streptococci. J Med Microbiol 1985; 19: 227-235.
335. Allen B W. Storage of mycobacteria at -20°C. Med Lab Sci 1986; 43: 390-392.
336. Allen B W. Isolation of Mycobacterium tuberculosis from faeces. Med Lab Sci 1989; 46: 101-106.
337. Devadatta S, Radhakrishna S, Fox W, Mitchison D A, RaJagopalan S, Sivasubramanian S, Stott H. Comparative value of sputum smear examination and culture examination in assessing the progress of tuberculous patients receiving chemotherapy. Bull World Health Organ 1966; 34: 573-587.
338. Andrews R H, Radhakrishna S. A comparison of two methods of sputum collection in the diagnosis of pulmonary tuberculosis. Tubercle 1959; 40: 155-162.
339. Velu S, Narayana A S L, Subbaiah T V. A comparison of the results of bacteriological examination of a sputum collection and a pair of laryngeal swab specimens in patients receiving chemotherapy for pulmonary tuberculosis. Tubercle 1962: 43; 1-10.
340. Joseph S, Nair N G K, Gangadharam P R J. A sputum swab culture method for tubercle bacilii using cetrimide compared with two other swab culture methods and the concentration culture method. Tubercle 1969; 50: 299-304.
341. Aber V R, Allen B W, Mitchison D A, Ayuma P, Edwards E A, Keyes A B. Quality control in tuberculosis bacteriologyy. I. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle 1980; 61: 123-133.
342. Mitchison D A, Keyes A B, Edwards E A, Ayuma P, Byfield S P, Nunn A J. Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short-course chemotherapy in Africa. Tubercle 1980; 61: 135-144.
343. Selkon J B, Mitchison D A. Viable counting of Mycobacteriutn tuberculosis in a silica gel medium. J Gen Microbiol 1957; 16: 229-235.
344. Gilani S, Selkon J B. The niacin test for differentiating human tubercle bacilli from other mycobacteria. Tubercle 1958; 39: 396-398.
345. Mitchison D A, Selkon J B. Atypical mycobacteria. Bull Int Union Tuberc 1959; 29: 358-368.
346. Selkon J B, Mitchison D A. Atypical mycobacteria and drug-resistant tubercle bacilli isolated during a survey of untreated patients with pulmonary tuberculosis. Tubercle 1959; 40: 141-154.
347. Thomas K L, Joseph S, Subhaiah T V, Selkon J B. Identification of tubercle bacilli from Indian patients with pulmonary tuberculosis. Bull World Health Organ 1961; 25: 747-758.
348. Lloyd J. A method for studying micro-colonial structure and cord formation. Tubercle 1960; 41: 281.
349. Csillag A. Periodic acid-schiff (PAS) staining of 'atypical' mycobacteria and tubercle bacilli. Tubercle 1960; 41: 63-67.
350. Csillag A. Morphological and biochemical features of 'atypical' mycobacteria. J Gen Microbiol 1960; 24: 261-272.
351. Allen B W. Mycobacterium xenopi. Eur J Respir Dis 1982; 63: 291-292.
352. Reggiardo Z, Aber V R, Mitchison D A, Devi S. Hemagglutination tests for tuberculosis with mycobacterial glycolipid antigens. Am Rev Respir Dis 1981; 124: 21-25.
353. Chan S L, Reggiardo Z, Daniel T M, Girling D J, Mitchison D A. Serodiagnosis of tuberculosis using an ELISA with Antigen 5 and a hemagglutination assay with glycolipid antigens. Am Rev Respir Dis 1990; 142: 385-390.
354. Coates A R M. Serology of tuberculosis. Eur J Respir Dis 1980; 61: 307-309.
355. Mitchison D A, Chalmers J. Musculoskeletal tuberculosis. In: Hughes S P F, Fitzgerald R H, eds. Musculoskeletal Infections. Chicago: Year Book Medical Publishers, 1986: pp 186-215.
356. Mitchison D A. Microbial genetics and chemotherapy. Br Med Bull 1962; 18: 74-80.
357. Mitchison D A. Drug resistance in mycobacteria. Br Med Bull 1984; 40: 84-90.
358. Mitchison D A, Selkon J B, Hay D, Stewart S M, Wallace A T. Solid and liquid medium tests of streptomycin sensitivity of Mycobacterium tuberculosis. Tubercle 1958; 39: 226-231.
359. Allen B W. Mycobacterium tuberculosis strain H37Rv. J Med Lab Tech 1969; 26: 389-390.
360. Selkon J B, Mitchison D A. A concept of drug resistance. Veterans Admin., Washington, USA. Trans. 17th Conference Proceedings 1958: pp 258-264.
361. Mitchison D A. Sensitivity tests. In: Heaf F, Rusly N L, eds. Recent Advances in Respiratory Tuberculosis. 6th ed. London: Churchill Livingstone, 1968: pp 160-182.
362. Mitchison D A. What is drug resistance? Tubercle 1969; 50 (Suppl): 44-47.
363. Canetti G, Fox W, Khomenko A, Mahler H T, Menon N K, Mitchison D A, Rist N, Smelev N A. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
364. Lefford M J. The ethionamide sensitivity of British pre-treatment strains of Mycobacterium tuberculosis. Tubercle 1966; 47: 198-206.
365. Lefford M J, Mitchison D A. Comparison of methods for testing the sensitivity of Mycobacterium tuberculosis to ethionamide. Tubercle 1966; 47: 250-262.
366. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler H T, Meissner G, Mitchison D A, Sula L. Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-578.
367. Tripathy S P, Mitchison D A, Nair N G K, Radhakrishna S, Subbamal S. A comparison of various measures of sensitivity of M. tuberculosis to pyrazinamide. Tubercle 1970; 51: 375-388.
368. Mitchison D A. Primary drug resistance. Proceedings of the 16th International Tuberculosis Conference, Toronto. Bull Int Union Tuberc 1962; 32: 81-99.
369. Dickmson J M, Allen B W, Mitchison D A. Slide culture sensitivity tests. Tubercle 1989; 70: 115-121.
370. Hong Kong Tuberculosis Treatment Services/British Medical Research Council Investigation. A study in Hong Kong to evaluate the role of pretreatmem susceptibility tests in the selection of regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1972; 106: 1-22.
371. Hong Kong Tuberculosis Treatment Services/British Medical Research Council. A study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regimens of chemotherapy for pulmonary tuberculosis - second report. Tubercle 1974; 55: 169-192.
372. Mitchison D A. Implications of the Hong Kong study of policies of sensitivity testing. Bull Int Union Tuberc 1972: 9-14.
373. Mitchison D A. Pretreatment sensitivity tests in the chemotherapy of tuberculosis. In: Tala E, ed. Postgraduate Meeting on Modern Treatment of Tuberculosis. Finland: University Central Hospital of Turku, 1972: pp 71-82.
374. Mitchison D A. The prognostic significance of in vitro sensitivity-testing in tuberculosis. In: Watt P J, ed. The control of chemotherapy. Edinburgh: Churchill Livingstone, 1969: 25-34.
375. Mitchison D A. Effect of initial drug resistance on short-course chemotherapy of pulmonary tuberculosis. Cur Chemother Immunother 1982: 1004-1005.
376. Singh B, Mitchison D A. Bactericidal activity of streptomycin and isoniazid against tubercle bacilli. Br Med J 1954; 1: 130-132.
377. Singh B, Mitchison D A. Bactericidal activity of streptomycin and isoniazid in combination with p-aminosalicylic acid against Mycobacterium tuberculosis. J Gen Microbiol 1955; 12: 76-84.
378. Singh B, Mitchison D A. The bactericidal activities of combinations of streptomycin, isoniazid, p-aminosalicylic acid (PAS), oxytetracycline (terramycin) and viomycin against Mycobacterium tuberculosis. J Gen Microbiol 1955; 13: 176-184.
379. Mitchison D A. Chemotherapy of tuberculosis: A bacteriologist's viewpoint. Br Med J 1965; 1: 1333-1340.
380. Mitchison D A. Treatment of tuberculosis. J R Coll Physicians Lond 1980; 14: 91-99.
381. Dickinson J M, Mitchison D A. In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle 1966; 47: 370-380.
382. Dickinson J M, Mitchison D A. Short-term intermittent chemotherapy of experimental tuberculosis in the guinea-pig. Tubercle 1966; 47: 381-393.
383. Dickinson J M, Mitchison D A. Suitability of rifampicin for intermittent adminstration in the treatment of tuberculosis. Tubercle 1970; 51: 82-94.
384. Dickinson J M, Mitchison D A. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 1970; 51: 389-396.
385. 14C by Mycobacterium tuberculosis. Am Rev Respir Dis 1972; 105: 519-527.
386. Awaness A M, Mitchison D A. Cumulative effects of pulsed exposures of Mycobacterium tuberculosis to isoniazid. Tubercle 1973; 54: 153-158.
387. Jackett P S, Aber V R, Mitchison D A. The relationship between nicotinamide adenine dinucleotide concentration and antibacterial activity of isoniazid in Mycobacterium tuberculosis. Am Rev Respir Dis 1977; 115: 601-607.
388. Dickinson J M, Aber V R, Mitchison D A. Studies on the treatment of experimental tuberculosis of the guinea-pig with intermittent doses of isoniazid. Tubercle 1973; 54: 211-224.
389. Dickinson J M, Mitchison D A. Efficacy of intermittent pyrazinamide in experimental murine tuberculosis. Tubercle 1991; 72: 110-114.
390. Guy A, Dickinson J M, Mitchison D A. Turning intermittent regimens into daily regimens using blister-packs. An exploration in murine tuberculosis. Tubercle Lung Dis 1993; 74: 310-316.
391. Dickinson J M, Mitchison D A. In vitro and in vivo studies to assess the suitability of anti-tuberculous drugs for use in intermittent chemotherapy regimens. Tubercle 1968; 49: 66-70.
392. Dickinson J. The suitability of new drugs for intermittent chemotherapy of tuberculosis. Scand J Resp Dis 1969; 50 (Suppl): 69, 91-98.
393. Mitchison D A, Dickinson J M. Laboratory aspects of intermittent drug therapy. Postgrad Med J 1971; 47: 737-741.
394. Mitchison D A. The principles of intermittent chemotherapy. Studia Pneumologia et Phtisologica Cechoslovaca 1971; 31: 288-296.
395. Mitchison D A, Selkon J B. The bactericidal activities of anti-tuberculous drugs. Am Rev Respir Dis 1956; 74S: 109-116.
396. Dickinson J M, Mitchison D A. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981; 123: 367-371.
397. Dhillon J, Mitchison D A. Influence of BCG-induced immunity on the bactericidal activity of isoniazid and rifampicin in experimental tuberculosis of the mouse and guinea-pig. Br J Exp Pathol 1989; 70: 103-110.
398. Khor M, Lowrie D B, Mitchison D A. Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro. Br J Exp Pathol 1986; 67: 707-717.
399. Khor M, Lowrie D B, Coates A R M, Mitchison D A. Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Br J Exp Pathol 1986; 67: 587-596.
400. Wallace J G. The heat resistance of tubercle bacilli in the lungs of infected mice. Am Rev Respir Dis 1961; 83: 866-871.
401. Dickinson J M, Aber V R, Mitchison D A. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 1977; 116: 627-635.
402. Mitchison D A, Dickinson J M, Bactericidal mechanisms in short-course chemotherapy. Bull Int Union Tuberc 1978; 53: 254-259.
403. Mitchison D A. Basic mechanisms of chemotherapy. Chest 1979; 76S: 771-781.
404. Mitchison D A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
405. Dickinson J M, Mitchison D A. Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle 1976; 57: 251-258.
406. Mitchison D A, Dhillon J, Sole K. Rifampicin-containing chemoprophylaxis regimens compared in Cornell model murine tuberculosis. Tubercle Lung Dis 1994; 75 (Suppl): 16.
407. Dickinson J, Guy A, Mitchison D A. Bioavailability of rifampicin in experimental murine tuberculosis. Antimicrob Agents Chemother 1992; 36: 2066-2067.
408. Dickinson J M, Mitchison D A. Experimental investigations of bacteriological mechanisms in short-course chemotherapy. Bull Int Union Tuberc 1977; 51: 79-86.
409. Mitchison D A. Concepts in the chemotherapy of tuberculosis. Cas Lek Cesk 1984; 123: 145-176.
410. Dhillon J, Mitchison D A. Activity and penetration of anti-tuberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254. Antimicrob Agents Chemother 1989; 33: 1255-1259.
411. Dhillon J, Mitchison D A. Activity in vitro of rifabutin, FCE22807, rifapentine and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis 1992; 145: 212-214.
412. Dhillon J, Mitchison D A. Action of pyrazinamide, isoniazid and rifampicin on M. microti in vitro and in mouse peritoneal macrophages. Tubercle Lung Dis 1994; 75 (Suppl): 13.
413. Mitchison D A. The Garrod Lecture. Understanding the chemotherapy of tuberculosis - current problems. J Antimicrob Chemother 1992; 29: 477-493.
414. Mitchison D A. Mechanisms of tuberculosis chemotherapy. J Pharm Pharmacol 1997; 49: 31-36.
415. Donald P R, Sirgel F A, Botha F J, Van de Wal B W, Parkin D P, Seifart H I, Mitchison D A. The early bactericidal activity of different dosages of isoniazid. Tubercle Lung Dis 1994; 75 (Suppl): 36.
416. Dickinson J M, Mitchison D A. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle 1987; 68: 183-193.
417. Dickinson J M, Mitchison D A. In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469a (SPA-S-565). Tubercle 1990; 71: 109-115.
418. Herbert D, Paramasivan C N, Venkatcsan P, Kubendiran G, Prahhakar R, Mitchison D A. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2296-2299.
419. Dhillon J, Allen B W, Hu Y-M, Coates A R M, Mitchison D A. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998; 2: 736-742.
420. Dhillon J, Mitchison D A. Effect of vaccines in a murine model of dormant tuberculosis. Tubercle Lung Dis 1994; 75: 61-64.
421. De wit D, Wootton M, Dhillon J, Mitchison D A. The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tubercle Lung Dis 1995; 76: 555-562.
422. Dhillon J, Dickinson J M, Sole K, Mitchison D A. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996; 40: 552-555.
423. Mitchison D A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147: 1062-1063.
424. Dickinson J M, Mitchison D A. Activity of the combination of fludalanine and cycloserine against mycobacteria in vitro. Tubercle 1985; 66: 109-115.
425. Dickinson J M, Mitchison D A. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68: 177-182.
426. Mitchison D A, Wallace J G, Bhatia A L, Selkon J B, Subbaiah T V, Lancaster M C. A comparison of the virulence in guinea-pigs of South Indian and British tubercle bacilli. Tubercle 1960; 41: 1-22.
427. Selkon J B, Suhbaiah T V, Bhatia A L, Radhakrishna S, Mitchison D A. A comparison of the sensitivity to P-aminosalicylic acid of tubercle bacilli from South Indian and British patients. Bull World Health Organ 1960; 23: 599-611.
428. Wallace J G, Mitchison D A, Rees R J W, Bhatia A L, Gahgadharam P R J. The virulence of South Indian tubercle bacilli in mice and guinea-pigs infected by the intravenous route. Tubercle 1961; 42: 212-217.
429. Subbaiah T V, Mitchison D A, Selkon J B. The susceptibility to hydrogen peroxide of Indian and British isoniazid-sensitive and isoniazid-resistant tubercle bacilli. Tubercle 1960; 41: 323-333.
430. Bhatia A L, Devadatta S, Mitchison D A, Radhakrishna S, Selkon J B, Subhaiah T V. The consistency of the virulence in the guinea-pig of tubercle bacilli isolated on different occasions from South Indian patients before treatment. Tubercle 1961; 42: 317-321.
431. Subbaiah T V, Ramachandran K. The consistency of the susceptihility to hydrogen peroxide of tubercle bacilli isolated from South Indian patients before treatment. Tubercle 1961; 42: 322-324.
432. Mitchison D A, Bhatia A L, Radhakrishna S, Selkon J B, Subbaiah T V, Wallace J G. The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. 1. Homogeneity of the investigation and a critique of the virulence test. Bull World Health Organ 1961; 25: 285-312.
433. Bhatia A L, Csillag A, Mitchison D A, Selkon J B, Somasundaram P R, Subbaiah T V. The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. 2. Comparison with virulence of tubercle bacilli from British patients. Bull World Health Organ 1961; 25: 313-322.
434. Ramakrishnan C V, Bhatia A L, Fox W, Mitchison D A, Radhakrishna S, Selkon J B, Subbaiah T V, Velu S, Wallace J G. The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. 3. Virulence related to pretreatment status of disease and to response to chemotherapy. Bull World Health Organ 1961; 25: 323-338.
435. Subbaiah T V, Bhatia A L, Geraghty E, Mitchison D A, Radhakrishna S, Selkon J B. The virulence in the guinea-pig of isoniazid-sensitive tubercle bacilli isolated from South Indian patients before treatment and after three months of chemotherapy. Bull World Health Organ 1961; 25: 759-764.
436. Mitchison D A. The epidemiology of tubercle bacilli. In: Ross J P, ed. The scientific basis of medicine. Annual Reviews. London: Athlone Press, 1963: pp 319-339.
437. Mitchison D A. The infectivity and pathogenicity of Indian tubercle bacilli. Am Rev Respir Dis 1963; 88: 267-268.
438. Mitchison D A, Selkon J B, Lloyd J. Virulence in the guinea-pig, susceptibility to hydrogen peroxide, and catalase activity of isoniazid-sensitive tubercle bacilli from South Indian and British patients. Journal of Pathology and Bacteriology 1963; 86: 377-386.
439. Dickinson J M, Lefford M J, Lloyd J, Mitchison D A. The virulence in the guinea-pig of tubercle bacilli from patients with pulmonary tuberculosis in Hong Kong. Tubercle 1963; 44: 446-451.
440. Bhatia A L, Jacob C V, Ramachandran K, Selkon J B. A comparison of the virulence in the guinea-pig of tubercle bacilli from Thai and British patients. Bull World Health Organ 1963; 29: 483-490.
441. Mitchison D A. The virulence of tubercle bacilli from patients with pulmonary tuberculosis in India and other countries. Bull Int Union Tuberc 1964; 35: 287-306.
442. Nair C N, Mackay-Scollay E M, Ramachandran K, Selkon J B, Tripathy S P, Mitchison D A, Dickinson J M. Virulence in the guinea-pig and susceptibility to hydrogen peroxide of isoniazid-sensitive tubercle bacilli from South Indian patients. Tubercle 1964; 45: 345-353.
443. Joseph S, Mitchison D A, Ramachandran K, Selkon J B, Subbaiah T V. Virulence in the guinea-pig and sensitivity to PAS and thiacetazone to tubercle bacilli from South Indian patients with pulmonary tuberculosis. Tubercle 1964; 45: 354-359.
444. Mitchison D A, Lloyd J. Comparison of the sensitivity to thiacetazone of tubercle bacilli from patients in Britain, East Africa, South India and Hong Kong. Tubercle 1964; 45: 360-369.
445. Lefford M J, Dickinson J M, Mitchison D A. The sensitivity to thiacetazone and para-aminosalicyclic acid and the virulence in the guinea-pig of East African strains of Mycobacterium tuberculosis. Tubercle 1969; 50: 1-6.
446. Bates J H, Mitchison D A. Geographic distribution of bacteriophage types of Mycobacterium tuberculosis. Am Rev Respir Dis 1969; 100: 189-193.
447. Mitchison D A. Regional variation in the guinea-pig virulence and other characteristics of tubercle bacilli. Pneumonology 1970; 142: 131-137.
448. Grange J M, Aber V R, Allen B W, Mitchison D A, Mikhail J R, Mcswiggan D A, Collins C H. Comparison of strains of Mycobacterium tuberculosis from British, Ugandan and Asian immigrant patients: A study in bacteriophage typing, susceptibility to hydrogen peroxide and sensitivity to thiophen-2-carbonic acid hydrazide. Tubercle 1977; 58: 207-215.
449. Grange J M, Aber V R, Allen B W, Mitchison D A, Goren M B. The correlation of bacteriophage types of Mycobacterium tuberculosis with guinea-pig virulence and in vitro-indicators of virulence. J Gen Microbiol 1978; 108: 1-7.
450. Goren M B, Grange J M, Aber V R, Allen B W, Mitchison D A. Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of Mycobacterium tuberculosis. Br J Exp Pathol 1982; 63: 693-700.
451. Bhatia L, Ramachandran K. The growth rate of tubercle bacilli from South Indian and British patients. Indian J Med Res 1962; 50: 335-342.
452. Mitchison D A. Natural sensitivity of M. tuberculosis to thiacetazone. Tubercle 1968; (Suppl): 38-46.
453. Barnett M, Dickinson J M. The response to treatment with thiacetazone of guinea-pigs and mice infected with tubercle bacilli obtained from untreated African patients. Tubercle 1963; 44: 417-30.
454. Lefford M J. The ethionamide sensitivity of East African strains of Mycobacterium tuberculosis resistant to thiacetazone. Tubercle 1969; 50: 7-13
455. Mitchison D A. Intectivity of patients with pulmonary tuberculosis during chemotherapy. Eur Resp J 1990; 3: 385-386.
456. Fox W. Compliance of patients and physicians: Experience and lessons from tuberculosis - I. Br Med J 1983; 287: 33-35.
457. Fox W. Compliance of patients and physicians: Experience and lessons from tuberculosis - II. Br Med J 1983; 287: 101-105.
458. Ellard G A, Gammon P T, Wallace S M. The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine. Biochem J 1972; 126: 449-458.
459. Ellard G A, Gammon P T. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4: 83-113.
460. Jenner P J, Ellard G A. Determination of the isoniazid metabolite monoacetylhydrazine in urine by high-performance liquid chromatography. J Chromatogr 1987; 245: 188-196.
461. Mitchison D A, Holt H D, Moore S H. Errors in the estimation of streptomycin in serum. J Clin Pathol 1949; 2: 213-216.
462. Mitchison D A, Spicer C C. A method of estimating streptomycin in serum and other body fluids by diffusion through agar enclosed in glass tubes. J Gen Microbiol 1949; 3: 184-203.
463. Lloyd J, Mitchison D A. A vertical diffusion method for the microbiological assay of isoniazid. J Clin Pathol 1964; 17: 622-626.
464. Dickinson J M, Aber V R, Allen B W, Ellard G A, Mitchison D A. Assay of rifampicin in serum. J Clin Pathol 1974; 27: 457-462.
465. Ellard G A. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 1969; 50: 144-158.
466. Ellard G A, Dickinson J M, Gammon P T, Mitchison D A. Serum concentrations and antituberculosis activity of thiacetazone. Tubercle 1974; 55: 41-54.
467. Jenner P J. High performance liquid Chromatographic determination of thiacetazone in body fluids. J Chromatog 1983; 276: 463-470.
468. Jenner P J, Ellard G A. High performance liquid chromatographic determination of ethionamide and prothionamide. J Chromatogr 1981; 225: 245-251.
469. Jenner P J, Ellard G A, Gruer P J K, Aber V R. A comparison of the blood levels and urinary excretion of ethionamide and prothionamide in man. J Antimicrob Chemother 1984; 13: 267-277.
470. Jenner P J, Smither S E. Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Lepr Rev 1987; 58: 31-37.
471. Rao K V N, Mitchison D A, Nair N G K, Prema K, Tripathy S P. Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. Br Med J 1970; 3: 495-497.
472. Viznerova A, Slavikova Z, Ellard G A. The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine. Tubercle 1973; 54: 67-76.
473. Ellard G A, Gammon P T, Tiitinen H. Determination of the acetylator phenotype from the ratio of the urinary excretion of acetylisoniazid to acid-labile isoniazid: A study in Finnish Lapland. Tubercle 1973; 54: 201-210.
474. Ellard G A, Gammon P T. The pharmacokinetics of isoniazid metabolism in man. In: Advances in Antimicrobial and Antineoplastic Chemotherapy. Munich: Urban and Schwarzenberg, 1972: pp 45-46.
475. Jenner P J, Ellard G A. Isoniazid-related hepatotoxicity: A study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle 1989; 70: 93-101.
476. Fawcett I W, Gammon P T. Determination of the acetylator phenotype in a northern Nigerian population. Tubercle 1975; 56: 199-201.
477. Ellard G A. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Therap 1976; 19: 610-625.
478. Ellard G A. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 1984; 65: 211-227.
479. Ellard G A. Signification clinique potentielle du phenotype d'acetylation de l'isoniazid dans la traitement de la tuberculose pulmonaire. Rev Francaise Mal Resp 1983; 1: 207-219.
480. Ellard G A. Potencialni klinicky vyznam fenotypu acetylace isoniazidu v lecbe plicni tuberkulozy. Lek Ces 1984; 123: 158-164.
481. Ellard G A, Girling D J, Nunn A J. The hepatotoxicity of isoniazid among the three acetylator phenotypes. Am Rev Respir Dis 1980; 123: 568-570.
482. Gurumurthy P, Krishnamurthy M S, Nazareth O, Parthasarathy P, Sarma R, Somasundaram P R, Tripathy S P, Ellard G A. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129: 58-61.
483. Ellard G A, Greenfield C. A sensitive urine-test method for monitoring the ingestion of isoniazid. J Clin Pathol 1977; 30: 84-87.
484. Gangadharam P R J, Mitchison D A, Subbaiah T V, Short E I. The detection of isoniazid in urine. Tubercle 1958; 39: 191-200.
485. Stark J E, Ellard G A, Gammon P T, Fox W. The use of isoniazid as a marker to monitor the self-administration of medicaments. Br J Clin Pharmacol 1975; 2: 355-358.
486. Ellard G A, Jenner P J, Downs P A. An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs. Br J Clin Pharmacol 1980; 10: 369-381.
487. Ellard G A, Jenner P J, Allen B W. Who is taking their tablets? Br Med J 1982; 285: 1660-1661.
488. Stanley J N A, Pearson J M H, Ellard G A. An investigation of dapsone compliance using an isoniazid-marked formulation. Lepr Rev 1983; 54: 317-325.
489. Stanley J N A, Pearson J M H, Ellard G A. Ethionamide, prothionamide and thiacetazone. Studies of patient compliance using isoniazid-marked formulations. Lepr. Rev. 1986; 57: 9-18.
490. Ellard G A, Kiran K U, Stanley J N A. Long-term prothionamide compliance: a study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid. Lepr Rev 1988; 59: 163-175.
491. Ellard G A, Pannikar V K, Jesudasan K, Christian M. Clofazimine and dapsone compliance in leprosy. Lepr Rev 1988; 59: 163-175.
492. Mitchison D A, Allen B W, Miller A B. Detection of rifampicin in urine by a simple microbiological assay. Tubercle 1970; 51: 300-304.
493. Rao K V N, Eidus L, Jacob C V, Tripathy S P. A simple test for the detection of pyrazinamide and cycloserine in urine. Tubercle 1965; 46: 199-205.
494. Venkataraman P, Eidus L, Ramachandran K, Tripathy S P. A comparison of various methods for the detection of isoniazid and its metabolites in urine. Tubercle 1965; 46: 262-269.
495. Macfadyen D M, Heffernan J F . Urine testing for isoniazid in the supervision of out-patient oral chemotherapy for pulmonary tuberculosis. The failure of a routine service. Bull World Health Organ 1967; 36: 847-852.
496. Venkataraman P, Eidus L, Tripathy S P. Method for the estimation of acetylisoniazid in urine. Tubercle 1968; 49: 210-216.
497. Venkataraman P, Eidus L, Tripathy S P, Vein S. Fluorescence test for the detection of ethionamide metabolites in urine. Tubercle 1967; 48: 291-296.
498. Subbammak S, Krishnamurthy D V, Tripathy S P, Venkataraman P. Concentrations of pyrazinamide attained in serum with different doses of the drug. Bull World Health Organ 1968; 39: 771-774.
499. Sarma G R, Immanuel C, Kailasam S, Kannapiran M, Nair N G K, Radhakrishna S. A modified method for the estimation of acetylisoniazid in urine. Indian J Med Res 1974; 62: 945-952.
500. Mitchison D A. The pharmacology of isoniazid in man. 1962: 267-279.
501. Carrada Bravo T, Ellard G A, Mitchison D A, Horsfall P A L. Reappraisal of the activity of morphazinamide against M. tuberculosis. Tubercle 1975; 56: 211-217.
502. Jenner P J, Ellard G A, Swai O B. A study of thiacetazone blood levels and urinary excretion in man, using high performance liquid chromatography. Lepr Rev 1984; 55: 121-128.
503. Forgan-Smith R, Ellard G A, Newton D, Mitchison D A. Pyrazinamide and other drugs in tuberculous meningitis. Lancet 1973; 374.
504. Ellard G A, Humphries M J, Gabriel M, Teoh R. The penetration of pyrazinamide into the cerebrospinal fluid of patients with tuberculous meningitis. Brit Med J 1987; i: 284-285.
505. Ellard G A, Humphries M J, Allen B W. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis 1993; 148: 650-655.
506. Allen B W, Ellard G A, Gammon P T, King R C, McDougall A C, Rees R J W, Weddell A G M. The penetration of dapsone, rifampicin, isoniazid and pyrazinamide into peripheral nerves. Br J Pharmacol 1975; 55: 151-155.
507. Ellard G A. Chemotherapy of tuberculosis for patients with renal impairment. Nephron 1993; 64: 169-181.
508. Ellard G A and Mitchison D A. Tuberculosis in patients having dialysis. Brit Med J (Correspondence) 1980; 1: 1186 and 1: 1535.
509. Ellard G A and Mitchison D A. Tuberculosis in patients having dialysis. Brit Med J (Correspondence) 1980; 1: 1186 and 1: 1535.
510. Mitchison D A, Selkon J B. Bacteriological aspects of a survey of the incidence of drug-resistant tubercle bacilli among untreated patients. Tubercle 1957; 38: 85-98.
511. Lefford M J, Mitchison D A, Tall R. Bacteriological aspects of the Second National Survey of Primary Drug Resistance in Pulmonary Tuberculosis, 1963. Tubercle 1966; 47: 109-129.
512. Miller A B, Tall R, Fox W, Lefford M J, Mitchison D A. Primary drug resistance in pulmonary tuberculosis in Great Britain: Second National Survey, 1963. Tubercle 1966; 47: 92-108.
513. Heffernan J F, Nunn A J, Peto J, Fox W. Pulmonary tuberculosis in Scotland: A national sample survey and follow-up (1968-70) 1. The characteristics of the cases notified in 1968. Tubercle 1975; 56: 253-267.
514. Heffernan J F, Nunn A J, Peto J, Fox W. Tuberculosis in Scotland: A national sample survey (1968-70). 2. A two-year follow-up of newly diagnosed respiratory tuberculosis notified in 1968. Tubercle 1976; 57: 161-175.
515. Heffernan J F, Nunn A J, Peto J, Fox W. A two-year follow-up of a national sample survey of new cases of respiratory tuberculosis notified in Scotland in 1968. Health Bulletin 1977; May: 139-144.
516. Medical Research Council Tuberculosis And Chest Diseases Unit. National survey of tuberculosis notifications in England and Wales, 1978-79. Br Med J 1980; 281: 895-898.
517. Medical Research Council. The geographical distribution of tuberculosis notifications in a national survey of England and Wales (1978-79). Tubercle 1982; 63: 75-88.
518. Medical Research Council Tuberculosis And Chest Diseases Unit. Tuberculosis in children in a national survey of notifications in England and Wales, 1978-79. Arch Dis Child 1982; 57: 734-741.
519. Medical Research Council Tuberculosis And Chest Diseases Unit. Treatment of pulmonary tuberculosis in patients notified in England and Wales in 1978-79: Chemotherapy and hospital admission. Thorax 1985; 40: 113-120.
520. Medical Research Council Tuberculosis And Chest Diseases Unit. National survey of notifications of tuberculosis in England and Wales in 1983. Br Med J 1985; 291: 658-661.
521. Medical Research Council Tuberculosis And Chest Diseases Unit. The geographical distribution of tuberculosis notifications in a national survey of England and Wales in 1983. Tubercle 1986; 67: 163-178.
522. Nunn A J, Darbyshire J H, Fox W, Johnson D A, Springett V H. Changes in annual tuberculosis notification rates between 1978/79 and 1983 for the population of Indian subcontinent ethnic origin resident in England. J Epidemiol Community Health 1986; 40: 357-363.
523. Humphries M J, Nunn A J, Byfield S P, Darbyshire J, Fox W, Citron K M. National survey of tuberculosis notifications in England and Wales in 1983: Characteristics of disease. Tubercle 1987; 68: 19-32.
524. Medical Research Council Tuberculosis And Chest Diseases Unit. Tuberculosis in children: A national survey of notifications in England and Wales in 1983. Arch Dis Child 1988; 63: 266-276.
525. Medical Research Council Tuberculosis And Chest Diseases Unit. Management and outcome of pulmonary tuberculosis in adults notified in England and Wales in 1983. Thorax 1988; 43: 591-598.
526. Medical Research Council Cardiothoracic Epidemiology Group. National survey of notifications of tuberculosis in England and Wales in 1988. Thorax 1992; 47: 770-775.
527. Meredith S K, Aber V R, Nunn A J, Byfield S P, Johnson D A, Darbyshire J H, Watson J M, Citron K M. Tuberculosis in children: A national survey of notifications in England and Wales in 1988. Arch Dis Child 1994; 70: 497-500.
528. The British Thoracic Society Research Committee And The Medical Research Council Cardiothoracic Epidemiology Group. The management of pulmonary tuberculosis in adults notified in England and Wales in 1988. Respir Med 1991; 85: 319-323.
529. Hong Kong Government/British Medical Research Council. Drug resistance in patients with pulmonary tuberculosis presenting at chest clinics in Hong Kong. Tubercle 1964; 45: 77-95.
530. East African/British Medical Research Council. Tuberculosis in Kenya: A national sampling survey of drug resistance and other factors. Tubercle 1968; 49: 136-167.
531. East African/British Medical Research Council. Tuberculosis in Kenya: a follow-up of a national sampling survey of drug resistance and other factors. Tubercle 1970; 51: 1-23.
532. East African/British Medical Research Council. Tuberculosis in Kenya: a second national survey of drug resistance and other factors, and a comparison with the prevalence data from the first national sampling survey. Tubercle 1978; 59: 155-177.
533. East African/British Medical Research Councils. Tuberculosis in Kenya: Follow-up of the second (1974) national sampling survey and a comparison with the follow-up data from the first (1964) national sampling survey. Tubercle 1979; 60: 125-149.
534. A Kenyan/British Medical Research Council Co-operative Investigation. Tuberculosis in Kenya 1984: a third national survey and a comparison with earlier surveys in 1964 and 1974. Tubercle 1989; 70: 5-20.
535. East African/British Medical Research Council. Tuberculosis in Tanzania: a national sampling survey of drug resistance and other factors. Tubercle 1975; 56: 269-294.
536. East African/British Medical Research Council. Tuberculosis in Tanzania: a follow-up of a national sampling survey of drug resistance and other factors. Tubercle 1977; 58: 55-78.
537. Tanzanian/British Medical Research Council Collaborative Study. Tuberculosis in Tanzania: a national survey of newly notified cases. Tubercle 1985; 66: 161-178.
538. Sutherland I, Springen V H, Nunn A J. Changes in tuberculosis notification rates in ethnic groups in England between 1971 and 1978/79. Tubercle 1984; 65: 83-91.
539. Nunn A J, Springett V H, Sutherland I. Changes in tuberculosis
540. Springen V H, Darbyshire J H, Nunn A J, Sutherland I. Changes in tuberculosis notification rates in the white ethnic group in England and Wales between 1953 and 1983. J Epidemiol Community Health 1988; 42: 370-376.
541. Davies P D O, Humphries M J, Byfield S P, Nunn A J, Darbyshire J H, Citron K M, Fox W. Bone and joint tuberculosis: A survey of notifications in England and Wales. J Bone Joint Surg [Br] 1984; 66-B: 326-330.
542. Joint Tuberculosis Committee Of The British Thoracic Association. Notification of tuberculosis: A code of practice for England and Wales. Br Med J 1982; 284: 1454-1456.
543. Pepys J, Mitchison D A, Kinsley B J. The prevalence of bacterial resistance to isoniazid and to PAS in patients with acute pulmonary tuberculosis presenting for treatment in East Africa. Tubercle 1960; 41: 32-36.
544. British Tuberculosis Association. Acquired drug resistance in patients with pulmonary tuberculosis in Great Britain - a national survey, 1960-61. Tubercle 1963; 44: 1-26.
545. Styblo K, Meijer J, Sutherland I. Tuberculosis Surveillance Research Unit Report no. 1. The transmission of tubercle bacilli: its trend in a human population. Bull Int Union Tuberc 1969; 152: 5-104.
546. Stott H, Patel A, Sutherland I, Thorup I, Smith P G, Kent P W, Rykushin Y P. The risk of tuberculous infection in Uganda, derived from the findings of National Tuberculin Surveys in 1958 and 1970. Tubercle 1973; 54: 1-22.
547. Nsanzumuhire H, Lukwago E W, Edwards E A, Stott H, Fox W, Sutherland I. A study of the use of community leaders on case-finding for pulmonary tuberculosis in the Machakos district of Kenya. Tubercle 1977; 58: 117-128.
548. Aluoch J A, Karuga W K, Nsanzumuhire H, Edwards E A, Stott H, Fox W, Sutherland I. A second study of the use of community leaders in case-finding for pulmonary tuberculosis in Kenya. Tubercle 1978; 59: 233-243.
549. Nsanzumuhire H, Aluoch J A, Karuga W K, Edwards E A, Stott H, Fox W, Sutherland I. A third study of case-finding methods for pulmonary tuberculosis in Kenya, including the use of community leaders. Tubercle 1981; 62: 79-94.
550. Aluoch J A, Edwards E A, Stott H, Fox W, Sutherland I. A fourth study of case-finding methods for pulmonary tuberculosis in Kenya. Trans R Soc Trop Med Hyg 1982; 76: 679-691.
551. Aluoch J A, Swai O B, Edwards E A, Stott H, Darbyshire J, Fox W, Sutherland I. Study of case-finding for pulmonary tuberculosis in outpatients complaining of a chronic cough at a district hospital in Kenya. Am Rev Respir Dis 1984; 129: 915-920.
552. Aluoch J A, Swai O B, Edwards E A, Stott H, Darbyshire J H, Fox W, Stephens R J, Sutherland I. Studies of case-finding for pulmonary tuberculosis in outpatients at 4 district hospitals in Kenya. Tubercle 1985; 66: 237-249.
553. Aluoch J A, Oyoo D, Swai B, Kwamanga D, Agwanda R, Edwards E A, Stott H, Darbyshire J H, Fox W, Sutherland I. A study of the use of maternity and child welfare clinics in case-finding for pulmonary tuberculosis in Kenya. Tubercle 1987; 68: 93-103.
554. Krishnaswami K V, Satagopan M C, Somasundaram P R, Tripathy S P, Radhakrishna S, Fox W. Address card for obtaining accurate addresses of clinic patients. Br Med J 1979; 1: 89.
555. Krishnaswami K V, Satagopan M C, Somasundaram P R, Tripathy S P, Radhakrishna S, Fox W. An investigation of the accuracy of the home address given by patients in an urban community in South India. Tubercle 1979; 60: 1-11.
556. Radhakrishna S, Satagopan M C, Krishnaswami K V, Tripathy S P, Vaidyanathan B, Fox W. A study of the accuracy, and factors influencing accuracy, of home addresses of patients obtained by registry clerks and address cards in four large towns in South India. Tubercle 1980; 61: 197-206.
557. Satagopan M C, Radhakrishna S, Krishnaswami K V, Somasundaram P R, Tripathy S P, Fox W. A novel system to obtain addresses of out-patients - assessment in routine clinic practice in Madras, South India. Tubercle 1984; 65: 41-45.
558. Krishnaswami K V, Somasundaram P R, Tripathy S P, Vaidyanathan B, Radhakrishna S, Fox W. A randomised study of two policies for managing default in out-patients collecting supplies of drugs for pulmonary tuberculosis in a large city in South India. Tubercle 1981; 61: 103-112.
559. Krishnaswami K V, Seshagiri K, Satagopan M C, Tripathy S P, Rahim M A, Radhakrishna S, Somasundaram P R, Fox W. Study of a policy to minimise the prescription of medicaments at first attendance at chest clinics. Lancet 1982: 483-486.
560. Fox W, Nunn A J. The cost of antituberculous drug regimens. Am Rev Respir Dis 1979; 120: 503-509.
561. Fox W, Prabhakar R, Ganapathy S, Somasundaram P R. An enquiry into the attitudes of South Indian patients to the coloration of their urine by ritampicin. Tubercle 1987; 68: 201-207.
562. Allan W G L, Snell N J C, Hill L E, Fayers P M, Scadding J G, Fox W. A survey of deaths in Hong Kong attributed to tuberculosis. Tubercle 1981; 62: 1-11.
563. Hong Kong Chest Service/British Medical Research Council. Survey of deaths in Hong Kong attributed to tuberculosis during a five-year period. Tubercle 1984; 65: 253-261.
564. Humphries M J, Byfield S P, Darbyshire J H, Davies P D O, Nunn A J, Citron K M, Fox W. Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest 1984; 78: 149-158.
565. Allan W G L, Girling D J, Fayers P M, Fox W. The symptoms of newly diagnosed pulmonary tuberculosis and patients' attitudes to the disease and to its treatment in Hong Kong. Tubercle 1979; 60: 211-223.
566. Hong Kong Chest Service/British Medical Research Council. Survey of the previous investigation and treatment by private practitioners of patients with pulmonary tuberculosis attending government chest clinics in Hong Kong. Tubercle 1984; 65: 161-171.
567. Hong Kong Chest Service/British Medical Research Council. Survey of patients presenting to the government chest service in Hong Kong and the effects of active tuberculosis case-finding by publicity campaigns. Tubercle 1984; 65: 173-184.
568. Hong Kong Chest Service/British Medical Research Council. A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Am Rev Respir Dis 1980; 122: 417-424.
569. Hong Kong Chest Service/British Medical Research Council. A service programme with a 6-month intensive chemotherapy regimen in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Tubercle 1983; 64: 265-274.
570. Davies P D O, Darbyshire J, Nunn A J, Byfield S P, Fox W, Citron K M, Raynes R H. Ambiguities and inaccuracies in the notification system for tuberculosis in England and Wales. Community Med 1981; 3: 108-118.
571. Fox W. Organisational and administrative considerations in the diagnosis of pulmonary tuberculosis in developing countries. Tubercle 1968; 49: 332-346.
572. Fox W. Short-course chemotherapy for pulmonary tuberculosis and some problems of its programme application with particular reference to India. Lung India 1984; 2: 161-174.
573. Fox W. Tuberculosis in India, past, present and future. Indian J Tuberc 1990; 37: 175-213.